HC Wainwright Analysts Lift Earnings Estimates for COGT

Cogent Biosciences, Inc. (NASDAQ:COGT) – HC Wainwright lifted their Q1 2026 EPS estimates for shares of Cogent Biosciences in a research note issued on Tuesday, March 17th. HC Wainwright analyst R. Burns now forecasts that the technology company will post earnings of ($0.53) per share for the quarter, up from their prior estimate of ($0.54). HC Wainwright has a “Buy” rating and a $52.00 price objective on the stock. The consensus estimate for Cogent Biosciences’ current full-year earnings is ($2.42) per share. HC Wainwright also issued estimates for Cogent Biosciences’ Q3 2026 earnings at ($0.56) EPS, Q4 2026 earnings at ($0.57) EPS and FY2026 earnings at ($2.21) EPS.

A number of other equities research analysts also recently issued reports on COGT. JPMorgan Chase & Co. boosted their price target on Cogent Biosciences to $67.00 and gave the company an “overweight” rating in a research note on Friday, December 19th. Needham & Company LLC reiterated a “hold” rating on shares of Cogent Biosciences in a research note on Monday, December 8th. Robert W. Baird set a $35.00 price objective on shares of Cogent Biosciences in a report on Thursday, February 19th. UBS Group upgraded shares of Cogent Biosciences to a “strong-buy” rating in a research report on Wednesday, January 7th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Cogent Biosciences in a report on Monday, December 29th. Two research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $43.45.

Cogent Biosciences Stock Down 3.0%

COGT stock opened at $34.37 on Thursday. Cogent Biosciences has a fifty-two week low of $3.72 and a fifty-two week high of $43.73. The business’s 50-day moving average is $37.32 and its two-hundred day moving average is $29.41. The company has a debt-to-equity ratio of 0.41, a quick ratio of 14.23 and a current ratio of 14.23. The company has a market cap of $5.58 billion, a price-to-earnings ratio of -15.91 and a beta of 0.47.

Cogent Biosciences (NASDAQ:COGT) last released its quarterly earnings results on Tuesday, February 17th. The technology company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.04).

Institutional Investors Weigh In On Cogent Biosciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Voya Investment Management LLC increased its stake in shares of Cogent Biosciences by 110.0% in the third quarter. Voya Investment Management LLC now owns 61,623 shares of the technology company’s stock worth $885,000 after purchasing an additional 32,279 shares in the last quarter. Federated Hermes Inc. lifted its stake in shares of Cogent Biosciences by 4,661,150.0% during the 3rd quarter. Federated Hermes Inc. now owns 93,225 shares of the technology company’s stock valued at $1,339,000 after buying an additional 93,223 shares in the last quarter. Campbell & CO Investment Adviser LLC purchased a new position in shares of Cogent Biosciences during the 3rd quarter valued at $885,000. Optimize Financial Inc bought a new position in Cogent Biosciences in the 3rd quarter worth $467,000. Finally, Candriam S.C.A. boosted its holdings in Cogent Biosciences by 123.3% in the 3rd quarter. Candriam S.C.A. now owns 954,209 shares of the technology company’s stock worth $13,702,000 after buying an additional 526,867 shares during the period.

Insider Buying and Selling

In other news, insider Jessica Sachs sold 82,642 shares of Cogent Biosciences stock in a transaction dated Friday, December 26th. The stock was sold at an average price of $38.70, for a total transaction of $3,198,245.40. Following the transaction, the insider directly owned 133,938 shares of the company’s stock, valued at $5,183,400.60. The trade was a 38.16% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider John Edward Robinson sold 90,000 shares of the business’s stock in a transaction that occurred on Friday, December 26th. The shares were sold at an average price of $38.74, for a total value of $3,486,600.00. Following the transaction, the insider owned 140,002 shares of the company’s stock, valued at approximately $5,423,677.48. This trade represents a 39.13% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 3,737,642 shares of company stock worth $136,600,345. Corporate insiders own 7.29% of the company’s stock.

Cogent Biosciences Company Profile

Cogent Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that modulate the tumor microenvironment. The company’s research centers on targeting colony-stimulating factor 1 receptor (CSF1R), a key regulator of tumor-associated macrophages that can promote tumor growth and immune evasion. By selectively inhibiting CSF1R, Cogent Biosciences aims to restore immune surveillance and enhance the efficacy of existing cancer treatments.

The company’s lead asset is an orally bioavailable CSF1R inhibitor that has advanced into early-stage clinical trials for various solid tumors.